Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02535286 · ClinicalTrials.gov registry record · Phase 1
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
A Phase 1 study of Chronic Lymphocytic Leukemia and Richter Syndrome, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 4
- Study locations
NCT02535286: Completed Phase 1 study of Chronic Lymphocytic Leukemia and Richter Syndrome, sponsored by TG Therapeutics.
NCT02535286 is a Phase 1 study of Chronic Lymphocytic Leukemia and Richter Syndrome that has completed, run by TG Therapeutics. The registered enrollment target is 27 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02535286, a Phase 1 study of Chronic Lymphocytic Leukemia and Richter Syndrome, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.
Primary Outcome
To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities
Conditions Studied
Interventions
- DRUG Umbralisib
- BIOLOGICAL ublituximab
- BIOLOGICAL TG-1501
Study Locations (4)
New York
- TG Therapeutics Investigational Trial Site - New York
North Carolina
- TG Therapeutics Investigational Trial Site - Durham
Pennsylvania
- TG Therapeutics Investigational Trial Site - Philadelphia
Washington
- TG Therapeutics Investigational Trial Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2015-09-18 |
| Est. Completion | 2021-11-04 |
| Phase | Phase 1 |
What the finished NCT02535286 record still lists
NCT02535286 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Umbralisib is the first listed.
NCT02535286 reports a single indexed study location in New York, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02535286 about?
NCT02535286 is a clinical study titled "Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation". The purpose of this study is to evaluate the safety and effectiveness of targeted immunotherapy in combination with ublituximab and umbralisib, in patients with advanced CLL or Richter's Transformation.
What is the current status of trial NCT02535286?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2015-09-18. Estimated completion is 2021-11-04.
What conditions does trial NCT02535286 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Richter Syndrome.
What interventions are being tested in trial NCT02535286?
The interventions under investigation include: Umbralisib (DRUG), ublituximab (BIOLOGICAL), TG-1501 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02535286?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02535286 being conducted?
This trial has 4 study locations across New York, North Carolina, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02535286's enrollment target sits among peer trials
27 142nd of 187 higher than 42 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI